Follicular lymphoma classification
Follicular lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Follicular lymphoma classification On the Web |
American Roentgen Ray Society Images of Follicular lymphoma classification |
Risk calculators and risk factors for Follicular lymphoma classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Follicular lymphoma may be classified according to WHO criteria into 3 groups: low grade follicular lymphoma, high grade follicular lymphoma and diffuse large B cell lymphoma.
Classification
1-According to the WHO criteria, the disease is morphologically graded into:[1]
- Grade 1 (<5 centroblasts per high-power field (hpf))
- Grade 2 (6–15 centroblasts/hpf)
- Grade 3 (>15 centroblasts/hpf)
- Grade 3A (centrocytes still present)
- Grade 3B (the follicles consist almost entirely of centroblasts)
2-The WHO 2008 update classifies
- Grades 1 and 2 now as low grade follicular lymphoma
- Grade 3A as high grade follicular lymphoma
- Grade 3B as diffuse large B cell lymphoma.
There are three variants of follicular lymphoma:[2]
1.Pediatric follicular lymphoma
- Involves cervical lymph nodes, other peripheral lymph nodes, or Waldeyer ring
- Typically have early stage disease
- Lacks BCL-2 protein expression and t(14;18)
2.Primary intestinal follicular lymphoma
- Occurs most commonly in the small intestine, and frequently involves the duodenum
- Duodenal follicular lymphoma
- Found in the second portion of the duodenum
- Present as multiple polyps
- Diagnosis is most often an incidental finding
- Most patients have localized disease
- Prognosis is excellent even without treatment
3.Other extranodal follicular lymphomas
- Usually have localized extranodal disease
- Systemic relapses are rare
- Testicular follicular lymphoma are reported with increased frequency in children, but also are reported in adults.
References
- ↑ "Follicular Lymphomas". Retrieved 2008-07-26.
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov